share_log

Allarity Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Epshinsky Alexander

Allarity Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Epshinsky Alexander

Allarity Therapeutics | 3:首次持股聲明-高管 Epshinsky Alexander
美股SEC公告 ·  09/18 16:08

Moomoo AI 已提取核心訊息

Alexander Epshinsky, the Chief Financial Officer of Allarity Therapeutics, Inc. (ALLR), has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 document dated 09/12/2024. The filing indicates that Epshinsky beneficially owns 55,555 common stock shares, which were granted as employment inducement awards in line with his appointment as CFO. These restricted stock units (RSUs) are set to vest in equal installments over three years, contingent upon his continued employment with the company. The inducement grant complies with Nasdaq listing rule 5635(c)(4), and the filing was completed on 09/18/2024.
Alexander Epshinsky, the Chief Financial Officer of Allarity Therapeutics, Inc. (ALLR), has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 document dated 09/12/2024. The filing indicates that Epshinsky beneficially owns 55,555 common stock shares, which were granted as employment inducement awards in line with his appointment as CFO. These restricted stock units (RSUs) are set to vest in equal installments over three years, contingent upon his continued employment with the company. The inducement grant complies with Nasdaq listing rule 5635(c)(4), and the filing was completed on 09/18/2024.
致富金融(臨時代碼)的首席財務官Alexander Epshinsky已在2024年09/12提交了一份證券利益所有人的初步聲明文件給SEC,據一份日期爲2024年09/12的Form 3文件顯示。該提交表明Epshinsky有權利擁有55555股普通股,這些股份是作爲其被任命爲首席財務官而獲得的就業誘因獎勵。這些受限股票單位(RSUs)將在三年內分期平均歸屬,取決於他在公司的繼續僱傭情況。誘因授予符合納斯達克上市規則5635(c)(4),提交日期爲2024年09/18。
致富金融(臨時代碼)的首席財務官Alexander Epshinsky已在2024年09/12提交了一份證券利益所有人的初步聲明文件給SEC,據一份日期爲2024年09/12的Form 3文件顯示。該提交表明Epshinsky有權利擁有55555股普通股,這些股份是作爲其被任命爲首席財務官而獲得的就業誘因獎勵。這些受限股票單位(RSUs)將在三年內分期平均歸屬,取決於他在公司的繼續僱傭情況。誘因授予符合納斯達克上市規則5635(c)(4),提交日期爲2024年09/18。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息